Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWC202404
- Development stage
- Unknown
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DWC202404 is a small molecule drug candidate developed by Daewoong Pharmaceutical for the treatment of hypertension. It is currently being evaluated in phase 3 clinical trials, primarily as part of a combination therapy with DWC202314. The precise mechanism of action for DWC202404 has not been disclosed and remains unknown, but it does not represent a novel mechanism. The drug is administered orally and has not yet received regulatory approval in any country. Daewoong Pharmaceutical, based in South Korea, specializes in innovative therapeutics across multiple therapeutic areas and leads the development and manufacturing efforts for this compound.
Beyond the preview
Go deeper on DWC202404.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DWC202404.